Flexion Therapeutics announced the FDA informed the company yesterday that a clinical hold has been placed on patient enrollment and dosing in an ongoing Phase IIb trial evaluating FX006 in patients with osteoarthritis (OA) of the knee. Flexion has not yet received written notice of the hold, but verbal communication from the FDA indicates it […]
[Free Report] Merck KGaA Ends Cancer Vaccine Trials; RTRX Takes Heat
Following the failure of tecemotide (formerly known as Stimuvax) in a Phase I/II study in Japanese patients, Merck has decided to discontinue all clinical development of the drug, including the Phase III START2 and INSPIRE non-small cell lung cancer trials. Tecemotide is a MUC1 antibody-specific immunotherapy licensed from biotech company Oncothyreon. It had previously failed […]
